Laurion Capital Management’s Myriad Genetics MYGN Stock Holding History

Laurion Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,443	Closed	-$65K	–	519
2026 Q1	$65K	Buy	+14,443	New	+$75.3K	﹤0.01%	336
2020 Q3	–	Sell	-23,606	Closed	-$268K	–	1051
2020 Q2	$268K	Buy	+23,606	New	+$335K	﹤0.01%	742
2017 Q3	–	Sell	-20,600	Closed	-$532K	–	1796
2017 Q2	$532K	Buy	+20,600	New	+$437K	﹤0.01%	1235
2015 Q3	–	Sell	-44,940	Closed	-$1.53M	–	848
2015 Q2	$1.53M	Buy	+44,940	New	+$1.53M	0.01%	410

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Laurion Capital Management's MYGN Position: Q2 2026 in Review

Laurion Capital Management sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 14,443 shares — an estimated $65K sold.

Laurion Capital Management first reported a position in MYGN in Q2 2015 and held it in 4 quarters. The position peaked at $1.53M in Q2 2015. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

Laurion Capital Management reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
Laurion Capital Management sold 14,443 Myriad Genetics shares in Q2 2026, an estimated $65K.
Laurion Capital Management first reported a position in Myriad Genetics in Q2 2015 and held it in 4 quarters.
Laurion Capital Management's Myriad Genetics position peaked at $1.53M in Q2 2015.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.